Aiolos Bio is revolutionizing treatments for respiratory diseases and immune conditions, aiming to deliver innovative therapies to patients and caregivers. With a seasoned team boasting over 30 FDA approvals, Aiolos Bio is developing effective treatments for asthma, rheumatoid arthritis, and IPF. The company focuses on a groundbreaking anti-TSLP asset, which is expected to enhance efficacy with less frequent dosing than current treatments. Aiolos Bio's mission is to reduce treatment burden and improve patient care through more efficacious therapies.

Register for Details

For more details on financing and valuation for Aiolos Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Updated on: Jul 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.